Mittie Doyle
Chief Medical Officer at Avalo Therapeutics, Inc. (AVTX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $3.0M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 1SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 67951,776 held (−1%) | $20.00 | $14K | -31.8% |
| Aug 19SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 1,00051,776 held (−2%) | $20.00 | $20K | -31.8% |
| Aug 12SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 67951,776 held (−1%) | $20.00 | $14K | -31.8% |
| Jul 29SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 1,00051,776 held (−2%) | $20.00 | $20K | -31.8% |
| Jul 2SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 4,65451,776 held (−8%) | $20.00 | $93K | -31.8% |
| Jun 25SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 1,45051,776 held (−3%) | $18.00 | $26K | -24.2% |
| Jun 1SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 67947,122 held (−1%) | $16.00 | $11K | -14.7% |
| May 19SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 3,0003,622 held (−45%) | $18.76 | $56K | -27.2% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 1,6793,622 held (−32%) | $16.00 | $27K | -14.7% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 27,53882,639 held (−25%) | $18.03 | $497K | -24.3% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 5,00077,639 held (−6%) | $19.65 | $98K | -30.5% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 44,94432,695 held (−58%) | $21.20 | $953K | -35.6% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 19,01513,680 held (−58%) | $22.41 | $426K | -39.1% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 10,0583,622 held (−74%) | $22.88 | $230K | -40.3% |
| Apr 8SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 3,9703,622 held (−52%) | $18.01 | $71K | -24.2% |
| Apr 3SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 6793,622 held (−16%) | $16.00 | $11K | -14.7% |
| Mar 18SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 25,4923,622 held (−88%) | $16.15 | $412K | -15.5% |
- Sell
Chief Medical Officer Mittie Doyle sold $14K of AVTX at $20.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Mittie Doyle sold $20K of AVTX at $20.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Mittie Doyle sold $14K of AVTX at $20.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Mittie Doyle sold $20K of AVTX at $20.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Mittie Doyle sold $93K of AVTX at $20.00 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Mittie Doyle sold $26K of AVTX at $18.00 — pre-scheduled 10b5-1 plan sale.